Rudi Thiel is currently Head of Quality Systems & Compliance and Senior Manager Quality Assurance at Biogen. On the latest steps in his career, he was leading the Operational Technology Operating Model – Program for Novartis Technical Operations. This program included all activities required in both IT and OT space in order to address the progressing IT / OT convergence for all manufacturing sites.

From 2012 – 2017 Rudi Thiel was the IT Project Lead for New Launch Facility (NSLF) at Novartis. He was responsible for all IT components for the new launch facility for solid forms in PharmOps Switzerland including Manufacturing Execution System (MES) as well as IT Infrastructure.
From 2009 until 2012, Rudi was Head of Risk, Compliance & Quality for Global TechOps IT at Novartis, being accountable for all activities related to risk, compliance & quality in Global TechOps IT, including functional reports in all TechOps sites. Before that, Rudi was Quality Manager Global TechOps IT and prior to that, held the position of Program Quality Manager, Pharma ERP Program (PEP) Program Manager for SAP implementation, all for Novartis and Novartis US.

During his professional career, among others, Rudi Thiel also worked Roche Pharma as Quality Manager for Global SAP Competence Center, for CSC Ploenzke Switzerland as Project & Quality Manager and he was IT Consultant for various projects in the pharmaceutical industry.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.